Trial Site Econ
🛡️ Public data only — no PHI permitted on this instance.
Clinical Trial Site Economics
Site-level P&L · therapeutic area mix · phase economics · sponsor relationship · cost structure — 1,585 corpus deals
Total Sites
41
Active Trials
277
Annual Revenue
$127.59M
Blended Margin
23.6%
Avg Enrollment
6.77%
Therapeutic Areas
10
Active Sponsors
12
Corpus Deals
1,585
Site Roster (Top 30 by Revenue)
| Site ID | Therapeutic Area | Active Trials | Screens | Enrollment Rate | Revenue ($M) | Op Margin | ROI / Study ($k) |
|---|---|---|---|---|---|---|---|
| SITE-001 | Oncology | 4 | 3,600 | 4.08% | $4.97 | 18.0% | $223.8 |
| SITE-002 | Oncology | 9 | 3,320 | 5.18% | $6.32 | 26.0% | $182.5 |
| SITE-003 | Oncology | 5 | 3,240 | 4.13% | $5.03 | 19.0% | $191.2 |
| SITE-004 | Oncology | 8 | 3,600 | 4.56% | $5.56 | 28.0% | $194.5 |
| SITE-005 | Oncology | 9 | 4,520 | 5.18% | $6.32 | 26.0% | $182.5 |
| SITE-006 | Oncology | 9 | 4,200 | 4.32% | $5.26 | 23.0% | $134.5 |
| SITE-007 | Oncology | 5 | 4,440 | 4.13% | $5.03 | 19.0% | $191.2 |
| SITE-008 | Oncology | 4 | 4,000 | 4.08% | $4.97 | 18.0% | $223.8 |
| SITE-009 | Cardiology | 5 | 3,669 | 6.45% | $3.56 | 22.0% | $156.5 |
| SITE-010 | Cardiology | 4 | 3,391 | 5.27% | $2.91 | 18.0% | $130.8 |
| SITE-011 | Cardiology | 4 | 3,021 | 6.39% | $3.52 | 21.0% | $184.9 |
| SITE-012 | Cardiology | 8 | 3,268 | 6.26% | $3.45 | 19.0% | $82.0 |
| SITE-013 | Cardiology | 7 | 3,484 | 5.46% | $3.01 | 21.0% | $90.3 |
| SITE-014 | Cardiology | 9 | 3,237 | 5.58% | $3.08 | 23.0% | $78.7 |
| SITE-015 | Neurology | 5 | 2,328 | 4.78% | $2.62 | 25.0% | $131.1 |
| SITE-016 | Neurology | 4 | 2,352 | 5.36% | $2.94 | 21.0% | $154.1 |
| SITE-017 | Neurology | 9 | 2,808 | 5.30% | $2.91 | 20.0% | $64.6 |
| SITE-018 | Neurology | 7 | 2,472 | 4.58% | $2.51 | 21.0% | $75.2 |
| SITE-019 | Neurology | 6 | 2,064 | 5.77% | $3.16 | 29.0% | $152.9 |
| SITE-020 | Dermatology | 8 | 6,360 | 8.59% | $2.22 | 19.0% | $52.8 |
| SITE-021 | Dermatology | 9 | 6,420 | 8.67% | $2.24 | 20.0% | $49.9 |
| SITE-022 | Dermatology | 9 | 6,060 | 8.16% | $2.11 | 29.0% | $68.1 |
| SITE-023 | Dermatology | 9 | 6,660 | 8.16% | $2.11 | 29.0% | $68.1 |
| SITE-024 | Endocrinology / Metabolic | 4 | 5,390 | 7.00% | $2.73 | 21.0% | $143.3 |
| SITE-025 | Endocrinology / Metabolic | 4 | 5,170 | 7.41% | $2.89 | 27.0% | $195.0 |
| SITE-026 | Endocrinology / Metabolic | 8 | 6,160 | 7.28% | $2.84 | 25.0% | $88.6 |
| SITE-027 | Endocrinology / Metabolic | 8 | 5,940 | 7.68% | $2.99 | 31.0% | $116.0 |
| SITE-028 | Immunology / Rheum | 6 | 3,332 | 6.44% | $3.27 | 29.0% | $158.3 |
| SITE-029 | Immunology / Rheum | 5 | 3,293 | 6.38% | $3.25 | 28.0% | $181.7 |
| SITE-030 | Immunology / Rheum | 5 | 3,603 | 5.68% | $2.89 | 31.0% | $179.2 |
Therapeutic Area Rollup
| Therapeutic Area | Sites | Active Trials | Med Revenue / Site ($M) | Med Enrollment Rate | Growth |
|---|---|---|---|---|---|
| Oncology | 8 | 53 | $5.14 | 4.23% | accelerating |
| Cardiology | 6 | 37 | $3.27 | 5.92% | stable |
| Neurology | 5 | 31 | $2.91 | 5.30% | accelerating |
| Dermatology | 4 | 35 | $2.17 | 8.38% | stable |
| Endocrinology / Metabolic | 4 | 24 | $2.87 | 7.35% | accelerating (GLP-1) |
| Immunology / Rheum | 4 | 23 | $3.07 | 6.03% | stable |
| Ophthalmology | 3 | 20 | $1.72 | 6.97% | stable |
| Psychiatry / CNS | 3 | 25 | $1.75 | 6.26% | accelerating (psychedelics) |
| Pediatrics | 2 | 13 | $1.17 | 7.16% | stable |
| Rare Disease | 2 | 16 | $2.72 | 19.80% | accelerating |
Phase Economics — Per-Site Revenue & Margin
| Phase | Site Payment ($k) | Patients/Site | Duration (mo) | Total Revenue ($k) | Typical Margin |
|---|---|---|---|---|---|
| Phase I | $285 | 24 | 18 | $685 | 24.0% |
| Phase II | $485 | 85 | 30 | $1,625 | 22.0% |
| Phase III | $1,250 | 325 | 42 | $4,850 | 18.0% |
| Phase IV / PMS | $185 | 120 | 24 | $525 | 28.0% |
| DCT (Decentralized) | $420 | 180 | 28 | $1,180 | 26.0% |
Sponsor Relationship Matrix
| Sponsor | Type | Active Trials | Completed LTM | Avg Fee ($k) | On-Time | Engagement |
|---|---|---|---|---|---|---|
| Pfizer | Large Pharma | 18 | 8 | $725 | 88.0% | repeat |
| Merck & Co | Large Pharma | 14 | 6 | $685 | 92.0% | repeat |
| Bristol Myers Squibb | Large Pharma | 12 | 5 | $820 | 85.0% | repeat |
| Eli Lilly | Large Pharma | 15 | 7 | $685 | 91.0% | repeat |
| AstraZeneca | Large Pharma | 11 | 4 | $620 | 82.0% | repeat |
| IQVIA (CRO) | CRO | 22 | 11 | $485 | 78.0% | pass-through |
| Parexel (CRO) | CRO | 18 | 8 | $425 | 80.0% | pass-through |
| Novartis | Large Pharma | 13 | 6 | $725 | 87.0% | repeat |
| Roche / Genentech | Large Pharma | 16 | 7 | $780 | 89.0% | repeat |
| Biogen | Specialty Biotech | 6 | 3 | $520 | 75.0% | repeat |
| Vertex | Specialty Biotech | 5 | 2 | $820 | 85.0% | repeat |
| Moderna | Specialty Biotech | 8 | 3 | $385 | 72.0% | growing |
Cost Structure
| Category | % of Revenue | Annual Cost ($M) | Trend |
|---|---|---|---|
| Clinical Staff (CRC/Coordinators) | 32.0% | $40.83 | stable |
| Physician Investigators | 18.0% | $22.97 | rising (wage pressure) |
| Facility / Lease / Utilities | 8.0% | $10.21 | stable |
| Lab & Imaging Pass-Through | 12.0% | $15.31 | stable |
| Patient Stipends / Travel | 4.0% | $5.10 | rising (DCT shift) |
| Recruitment / Patient Acquisition | 5.0% | $6.38 | rising |
| Technology / eSource / CTMS | 3.0% | $3.83 | stable |
| Regulatory / IRB / Compliance | 4.0% | $5.10 | rising |
| Corporate / G&A | 6.0% | $7.66 | stable |
Trial Site Thesis: 41 sites running 277 active trials at $127.59M revenue, 23.6% operating margin.
Oncology and rare-disease therapeutic areas lead on revenue-per-site and enrollment rate; metabolic (GLP-1) and CNS (psychedelics) are fastest-growing. Phase IV and DCT drive highest margins at 28%.
Large pharma direct relationships (Pfizer, Merck, Lilly) generate highest per-study fees; CRO pass-through adds volume but lower margin.
Rising wage pressure on CRC/physician investigators and recruitment cost compression are the material operating headwinds to monitor.